Highlights Botanix Pharmaceuticals Limited

Equities

BOT

AU000000BOT2

Delayed Australian S.E. Other stock markets 06:25:39 26/06/2024 am IST			5-day change	1st Jan Change
0.3475 ^AUD	-4.79%		-2.78%	+84.21%

21/06	Botanix Pharmaceuticals to Raise AU$70 Million via Institutional Placement	MT
20/06	Botanix Pharmaceuticals Secures US FDA Approval for Topical Medication	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Botanix Pharmaceuticals Secures US FDA Approval for Topical Medication	20/06	MT
Botanix Pharmaceuticals Submits Last Label Materials for Sofdra FDA Approval	12/06	MT
Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
US FDA Accepts Resubmission of Botanix Pharmaceuticals' Topical Medication	22/01	MT
Botanix Pharmaceuticals Completes US FDA Resubmission for Topical Medication; Shares Gain 3%	21/12	MT
Botanix Pharmaceuticals Completes Human Factors Validation Study for Topical Medication; Shares Rise 3%	14/12	MT
Botanix Pharmaceuticals Secures US FDA Feedback for Topical Medication	04/12	MT
Botanix Pharmaceuticals Limited Receives Feedback from FDA	04/12	CI
Botanix Pharmaceuticals Signs Telehealth Deal for Dermatological Product	24/23/24	MT
Botanix Pharmaceuticals Secures Conditional US FDA Clearance for Use of 'Sofra' Trade Name	17/23/17	MT
Botanix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Botanix Pharmaceuticals Partner Secures Sublicense, Distribution Deal in Korea	05/23/05	MT
Botanix Pharmaceuticals to Raise AU$10 Million in Placement	05/23/05	MT
US FDA Completes Mid-Cycle Review of Botanix Pharmaceuticals’ Dermatological Drug	03/23/03	MT
Botanix Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/23/28	CI
Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review	08/22/08	CI
Botanix Pharmaceuticals Secures $2 Million R&D Tax Rebate for FY22	26/22/26	MT
Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study	13/22/13	CI
Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide	26/22/26	CI
Botanix Pharmaceuticals to Raise $5 Million in Placement; Shares Slump 10%	02/22/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Botanix Pharmaceuticals Limited

Equities

BOT

AU000000BOT2

Highlights

Filters